Advagene Biopharma Co., Ltd.
TWO: 6709.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yu-Shen Hsu
- Employees
- 12
- Headquarters
- Taipei, Taiwan
- IPO year
- 2018
- Market cap
- NT$1.5B
- Website
- https://www.advagene.com.tw
Loading 6709…
Loading profile data…Frequently asked questions about 6709
What does Advagene Biopharma Co., Ltd. (6709.TWO) do?
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. Its products in development include nasal spray influenza vaccine, allergy vaccines, and COVID-19 immunotherapy. The company is based in Taipei, Taiwan.
Where does 6709.TWO trade?
Advagene Biopharma Co., Ltd. (6709.TWO) trades on the Taipei Exchange.
What sector is 6709.TWO in?
Advagene Biopharma Co., Ltd. (6709.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Advagene Biopharma Co., Ltd.?
Yu-Shen Hsu is the chief executive officer of Advagene Biopharma Co., Ltd. (6709.TWO).
Where is Advagene Biopharma Co., Ltd. headquartered?
Advagene Biopharma Co., Ltd. is headquartered in Taiwan.
Does 6709.TWO pay a dividend?
Advagene Biopharma Co., Ltd. (6709.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6709.TWO go public?
Advagene Biopharma Co., Ltd. (6709.TWO) completed its initial public offering in 2018.